Showing 4811-4820 of 5957 results for "".
- Eyenovia Announces Appointment of Julia Haller, MD, to its Board of Directorshttps://modernod.com/news/eyenovia-announces-appointment-of-julia-haller-md-to-its-board-of-directors/2479041/Eyenovia announced the appointment of Julia Haller, MD, to its Board of Directors. “We are delighted to welcome Dr. Haller to our Board of Directors at such an exciting time for Eyenovia,” Sean Ianchulev, MD, PhD, Chief Executive Officer and Chief Medical
- Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Study for Lytenavahttps://modernod.com/news/outlook-therapeutics-reports-positive-safety-profile-from-norse-three-study-for-lytenava/2479037/Outlook Therapeutics announced positive topline results from its NORSE THREE open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) to treat retinal diseases. Topline results from the open-label safety study demonstrated that ONS-5010 showed no unexpecte
- Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept Agreement for Two Ophthalmic Drug Candidateshttps://modernod.com/news/nanoform-and-nacuity-pharmaceuticals-sign-technology-proof-of-concept-agreement-for-two-ophthalmic-drug-candidates/2479035/Nanoform Finland and Nacuity Pharmaceuticals announced that they have signed a Technology Proof of Concept Agreement, with compensation on standard commercial terms. This will apply Nanoform’s nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity’s NPI-001 and N
- AffaMed Therapeutics and SIFI Announce Joint Venture to Serve Greater China Markethttps://modernod.com/news/affamed-therapeutics-and-sifi-announce-joint-venture-to-serve-greater-china-market/2479036/AffaMed Therapeutics and SIFI S.p.A. announced they have entered into an agreement to establish a joint venture to develop, manufacture and commercialize premium IOLs in the Greater China market, including Mainland China, Taiwan, Macau and Hong Kong. AffaMed will provide funding for growth
- Surface Ophthalmics Announces Preeya K. Gupta, MD, as Chief Medical Advisorhttps://modernod.com/news/surface-ophthalmics-announces-preeya-k-gupta-md-as-chief-medical-advisor/2479032/Surface Ophthalmics announced the appointment of Preeya K. Gupta, MD, as Chief Medical Advisor (CMA). Dr. Gupta will consult with Surface Ophthalmics leaders and lend her expertise, particularly in dry eye disease, to help guide Surface’s three clinical progra
- FDA Approves Rayner’s RayOne EMV IOLhttps://modernod.com/news/fda-approves-rayners-rayone-emv-iol/2479019/Rayner’s RayOne EMV fully preloaded non-diffractive IOL has received FDA approval. RayOne EMV was developed in collaboration with renowned surgeon Professor Graham Barrett, president of the Australasian Society of Cataract & Refractive Surgeons. Dr. Mariano Royo, Director
- Gyroscope Therapeutics Announces $148 Million Raised in Series C Financinghttps://modernod.com/news/gyroscope-therapeutics-announces-148-million-raised-in-series-c-financing/2479018/Gyroscope Therapeutics announced it has raised $148.0 million (£107.8 million) in a Series C financing. Gyroscope plans to use proceeds from the financing to advance the clinical development of GT005,
- Intel AI-Powered Backpack Helps Visually Impaired Navigate Worldhttps://modernod.com/news/intel-ai-powered-backpack-helps-visually-impaired-navigate-world/2479014/Artificial intelligence (AI) developer Jagadish K. Mahendran and his team designed an AI-powered, voice-activated backpack that can help the visually impaired navigate and perceive the world around them. The backpack helps detect common challenges such as traffic signs, hanging obstacles, crosswa
- Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen for Dry AMD With Geographic Atrophyhttps://modernod.com/news/lineage-cell-therapeutics-presents-additional-interim-data-on-opregen-for-dry-amd-with-geographic-atrophy/2479007/Lineage Cell Therapeutics announced new positive interim results from its ongoing, 24-patient phase 1/2a clinical study of its lead product candidate, OpRegen. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal
- ProQR Announces Positive Results From Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trialshttps://modernod.com/news/proqr-announces-positive-results-from-clinical-trial-of-qr-421a-in-usher-syndrome-and-plans-to-start-pivotal-trials/2479006/ProQR Therapeutics announced results from a planned analysis of its phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. In the trial, QR-421a demonstrated benefit on multiple measures of v